FDA advisory committee unanimously recommends approval of biosimilar to Enbrel – Perspective by Seth Ginsberg

The overall aim of biosimilar is to help contribute toward the reduction of cost for patients. Among the important attributes for the arthritis community specifically is biosimilar confidence. That is confidence on the patient’s part, as well as the prescriber’s part, that the medication is going to be safe and effective as the originator product. Without biosimilar confidence, there could be massive tension for disruption and negativity.
 
Click here to read more.